Core Insights - The report by AppsFlyer highlights the profound impact of AI technology, scaled content production, and rising customer acquisition costs on the mobile gaming marketing landscape in 2025 [1][4][11] Group 1: AI as a Core Driver - AI technology has become the most significant transformative force in mobile game marketing, leading to a 20% increase in ad display volume due to enhanced material production capabilities [4] - Top-tier advertisers are producing 2,400 to 2,600 material versions quarterly, marking a 25% to 30% year-on-year growth [4] - The benefits of AI are unevenly distributed, primarily favoring top and small-scale advertisers, while mid-sized firms see limited advantages [4][11] Group 2: Global Customer Acquisition Landscape - Global customer acquisition spending for game applications reached $25 billion in 2025, reflecting a 3.8% year-on-year growth, with notable regional disparities [5][6] - The U.S. market, while still the largest, saw a 5% decline in spending, whereas emerging markets like Turkey (29% growth) and India (19% growth) are driving overall growth [5][6] - Chinese firms contributed 35% to global customer acquisition spending, with a 22% year-on-year increase, showcasing their strength in competitive Western markets [6][7] Group 3: Platform and Channel Trends - iOS is emerging as a growth focus, while Android is experiencing a contraction, attributed to the effective adaptation of probabilistic attribution techniques [8][9] - The average number of media channels used by advertisers has increased, with top-tier advertisers utilizing more channels than smaller ones [9] - The paid activation rate for all game categories has risen by approximately 10% year-on-year, indicating intensified competition and rising acquisition costs [8] Group 4: Monetization Model Evolution - In-app purchase (IAP) revenue remains concentrated in mature markets, with the U.S. and Europe contributing significantly to Android and iOS IAP revenues [10] - Mixed monetization strategies are gaining traction, although they still account for less than 30% of total revenue, with a clear upward trend [10] - Casual and hyper-casual games are more receptive to mixed monetization, while mid-core and gambling games prefer IAP as their primary revenue source [10]

Core Insights - The core theme of the meeting is "Striving for New Heights," emphasizing the importance of seizing opportunities in the AI era and focusing on the Dola assistant application as a short-term goal for the company [1][2] Group 1: AI Strategy and Business Focus - The company aims to leverage AI technology to enhance user experience and creativity, aligning with its mission to "inspire creativity and enrich life" [2] - The Dola assistant application is identified as a key focus area, with the potential for expansion into various AI functionalities, including image generation and programming [2][3] - The company recognizes significant opportunities in the B2B sector through Model as a Service (MaaS), which has seen rapid growth in the past year [3] Group 2: Talent Investment and Compensation - The company plans to increase talent investment and enhance compensation competitiveness globally, including a 35% increase in performance evaluation cycles and a 1.5 times increase in salary adjustments compared to the previous period [3] - The goal of the new incentive policies is to ensure that employee compensation and incentives are leading in global markets, reflecting the company's commitment to human capital as a key investment [3] Group 3: Strategic Focus and Organizational Culture - The company emphasizes the need for strategic focus in business operations, promoting integration and collaboration while enhancing operational efficiency [4] - A culture of entrepreneurship is encouraged, with a focus on leadership principles and accountability to support the company's ambitious goals [4]

随着奥布替尼（商品名：宜诺凯 ）独家适应症边缘区淋巴瘤（MZL）的不断放量以及一线治疗慢性淋 巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）新适应症获批上市，以及坦昔妥单抗（商品名：明诺 凯 ）成为中国首个获批治疗复发/难治性弥漫大B细胞淋巴瘤（DLBCL）的CD19单抗，诺诚健华2025年 的药品收入实现快速增长。 经财务部门初步测算，诺诚健华预计2025年实现收入23.7亿元左右，与上年同期相比增长约134%。与 此同时，公司预计2025年归母净利润首次扭亏为盈，达到6.3亿元左右。这主要归功于商业化的持续放 量和全球商务拓展（BD）获得的收入。 1月29日，诺诚健华发布截至2025年12月31日的2025年年度业绩预告。 ...

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, has received acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection for domestic production [1] Group 1: Product Information - Fuxin Qibai monoclonal antibody is a fully human anti-IL-1β monoclonal antibody that specifically blocks the binding of IL-1β to its receptor, thereby inhibiting the activation of downstream signaling pathways [1] - The drug is primarily used for the treatment of non-infectious uveitis, and there are currently no similar drugs approved for the same disease area in both domestic and international markets [1]

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 1月29日，据北银理财披露，该公司发行的京华远见春系列智远封闭式23号理财产品募集期为2026年1月 29日至2026年2月4日，投资起点为1元。产品类型为固定收益类、非保本浮动收益型，产品风险评级为 较低风险产品（PR2），产品存续期限740天，业绩比较基准为2.5%-3.5%。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 ...

1月29日，据高盛工银理财披露，该公司发行的盛景封闭式固定收益类美元理财产品235期募集期为2026 年1月29日-2026年2月4日。A类份额首次认购1美元起购，B类份额首次认购2000美元起购。产品投资性 质为固定收益类，内部风险评级为PR1低风险，产品期限361天。A类份额业绩比较基准2.65%-2.95% （年化），B类份额业绩比较基准2.70%-3.00%（年化）。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 ...

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 1月29日，据苏银理财披露，该公司发行的恒源目标盈79期募集期为2026年1月29日至2026年2月4日。A 份额购买起点1元，计划发行规模为10亿元。产品类型为固定收益类、公募、封闭式，内部风险评级为 二级（PR2），产品存续期限763天，A份额业绩比较基准（年化）2.30%-3.30%。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 ...

以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 1月29日，据宁银理财披露，该公司发行的皎月全球配置挂钩型封闭式理财131号募集期为2026年1月29 日至2026年2月4日。个人投资者1元起售，机构投资者1元起售。产品最低成立规模1000万元，产品规模 上限为10亿元。产品类型为固定收益类、非保本浮动收益型，产品评级为PR2，产品期限749天，业绩 比较基准为1.60%-4.60%（年化）。 ...

(编辑：杨燕 林辰) （阿斯利康公众号） 1月29日，阿斯利康宣布，计划于2030年前在中国投资逾1000亿元人民币（150亿美元），以扩大在药品 生产与研发领域的布局。公司将充分发挥中国的科研优势和先进制造能力，并依托中英医疗健康生态系 统之间的协同合作，为中国及全球患者带来前沿创新疗法。 阿斯利康全球首席执行官苏博科表示，今天宣布的这笔逾1000亿元人民币的重大投资，开启了阿斯利康 在华发展的新篇章。中国已成为科学创新、先进制造和全球公共卫生领域的重要力量。通过进一步扩展 我们在细胞治疗、放射偶联药物等突破性疗法的能力，阿斯利康将为中国高质量发展作出更大贡献，更 重要的是，把下一代创新疗法带给更多患者。 ...

（企业公告） 对于业绩变动的原因，公告说明，2025年，风电叶片用环氧树脂产品销售实现大幅增长，带动利润同步 增长。其中，受益于风电行业景气度上升，风电叶片用环氧树脂产品需求旺盛，同时，公司积极拓展海 外市场，发展海外客户，公司风电叶片用环氧树脂销量较2024年实现明显增长；同时公司新型复合材料 用环氧树脂产品和电子电气绝缘封装用环氧树脂产品的收入相比去年同期都有所提升，从而导致业绩增 长。 1月29日，惠柏新材发布业绩预告，预计2025年度归属于上市公司股东的净利润为6200万元至7500万 元，同比增长672.68%至834.70%。 ...